The most comprehensive information available from a non-invasive prenatal test to date.
Karyo test couples leading technology with unparalleled insights to offer the most advanced information available from a non-invasive test. PrenatalSAFE®
Karyo is a cell-free fetal DNA (cfDNA)-based noninvasive prenatal test that analyzes every chromosome in the fetal genome.
Like most NIPTs, it can screen for common chromosomal abnormalities, such as Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 13 (Patau Syndrome) and sex chromosome aneuploidies (Monosomy X, Trisomy X, XXY and XYY). But it can also find other chromosomal changes that may go undiagnosed at birth, such as structural chromosomal aberrations (deletions or duplications), rare aneuploidies (e.g. Trisomy 9, 16, 22), across the entire fetal genome, and analyzes 9 clinically significant microdeletion regions, something other NIPTs do not currently do.